Clinical Trial Update: Isosorbide Mononitrate For Anti-Vascular Endothelial Growth Factor (VEGF) Induced Kidney Injury [Phase 2]

View source ↗

Summary

Phase 2 trial of isosorbide mononitrate for anti-VEGF–induced kidney injury was terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Injury
• Proteinuria

Drugs mentioned

• Isosorbide Mononitrate (isosorbide mononitrate)

Snippet

Sponsor: The University of Texas Health Science Center, Houston | Conditions: Kidney Injury, Proteinuria | Phase 2 | Status: TERMINATED | Results posted: 2022-08-03